Low Cost Sensor Developed To Diagnose Cystic Fibrosis

Cystic fibrosis is a common genetic disease within the white population in the United States. The disease occurs in 1 in 2,500 to 3,500 white newborns.

Penn State biomaterials scientists have developed a new, inexpensive method to detect salt concentrations in sweat or other bodily fluids.

The fluorescent sensor, derived from citric acid molecules, is highly sensitive and highly selective for chloride, the key diagnostic marker in cystic fibrosis.

Research Provides New Insight Into Underlying Mechanism Of Cystic Fibrosis & Associated �Gender Gap�
In females, estrogen interferes with the protein channel complex,worsening the effects of CF and leading to higher mortality rates and shorter a lifespan.

‘Naturally fluorescing polymer nanoparticles can be used to detect a key marker of cystic fibrosis.’

“Salt concentrations can be important for many health-related conditions,” said Jian Yang, professor of biomedical engineering. “Our method uses fluorescent molecules based on citrate, a natural molecule that is essential for bone health.”

Compared to other methods used for chloride detection, Yang’s citrate-based fluorescent material is much more sensitive to chloride and is able to detect it over a far wider range of concentrations. Yang’s material is also sensitive to bromide, another salt that can interfere with the results of traditional clinical laboratory tests. Even trace amounts of bromide can throw off test results. With the citrate-based sensor, Yang’s group can distinguish the difference between chloride and bromide, and are working to establish a possible new standard for bromide detection in diagnosis of the disease.

Yang is collaborating with Penn State electrical engineer, Professor Zhiwen Liu, to build a handheld device that can measure salt concentrations in sweat using his citrate-based molecules and a cell phone. This could also be useful in developing countries where people have limited access to expensive analytical equipment.

Improving and Prolonging the Life of a Child With Cystic Fibrosis
Adding specific DNA sequencing to current newborn screenings would allow for early diagnosis and may increase the number of cystic fibrosis diagnoses in the US.

“We are developing a platform material for sensing that is low cost, can be automated, requires no titration by trained staff or expensive instrumentation as in hospitals, and provides fast, almost instantaneous, results,” he said.

In a paper titled “Citrate-based fluorescent materials for low-cost chloride sensing in the diagnosis of Cystic Fibrosis,” recently published online in a Royal Society of Chemistry (RSC) journal Chemical Science, Yang compared their citrate sensors against the gold standard sweat test performed in a clinical laboratory. Their results were similar.

Uncategorized Genetic Mutations in Cystic Fibrosis
Cystic Fibrosis is a progressive genetic disease that causes persistent lung infections, clogs the airways and limits the ability to breathe over time.

“Beyond cystic fibrosis, our platform can also be used for many other diseases, such as metabolic alkalosis, Addison’s disease, and amyotrophic lateral sclerosis (ALS). All of those diseases display abnormal concentrations of chloride in the urine, serum or cerebral spinal fluid,” Yang said.

According to the U.S. National Library of Medicine, “Cystic fibrosis is a common genetic disease within the white population in the United States. The disease occurs in 1 in 2,500 to 3,500 white newborns. Cystic fibrosis is less common in other ethnic groups, affecting about 1 in 17,000 African Americans and 1 in 31,000 Asian Americans.”

Newborn Screening for Cystic Fibrosis Helps Early Detection
Cystic Fibrosis is caused by mutations in the CFTR gene that mainly affects the respiratory and digestive systems leading to to pulmonary chronic infection.

Robert Vender, M.D., a pulmonary specialist at Penn State Milton S. Hershey Medical Center who treats cystic fibrosis patients, says, “According to recommendations from the CF Foundation (Bethesda, MD) all patients undergoing evaluation for possible diagnosis of CF should have sweat testing performed. To date, measurements of sweat chloride (mmol/L) are only used for diagnostic purposes. However given the recent scientific and medical advances in CF patient directed therapy and the development and FDA approval of therapies specifically designed to modify cystic fibrosis transmembrane conductance regulator (CFTR) protein function, serial measurements of sweat chloride may have potential as a therapeutic surrogate indicator of drug effect and is currently measured in many pharmaceutical industry sponsored studies as a response to these novel treatments. The link between the surrogate marker of sweat chloride and actual objective clinical outcomes such as improved lung function still remains to be determined.” Lead author Jimin Kim, a graduate student in Yang’s lab, says, “Our citrate-based platform for designing fluorescent sensors provide us with great versatility in tailoring sensors to specific applications. We hope to produce more sensors with interesting applications in the near future.”

Also contributing to this work are Yang’s former postdoctoral fellow Dr. Zhiwei Xie and Michael Creer, M.D., a professor in the Penn State College of Medicine and chief of clinical pathology along with his colleague, Chris Pederson, who verified the results in clinical laboratory, and the previously mentioned professor of electrical engineering, Zhiwen Liu.

This work was supported in part by grants from the National Institutes of Health and the National Science Foundation.

Source-Newswise